Multi-system diseases and death trajectory of metabolic dysfunction-associated fatty liver disease: findings from the UK Biobank

被引:6
作者
Jia, Yu [1 ]
Li, Dongze [2 ]
You, Yi [3 ]
Yu, Jing [2 ]
Jiang, Wenli [1 ]
Liu, Yi [2 ]
Zeng, Rui [4 ]
Wan, Zhi [2 ]
Lei, Yi [1 ]
Liao, Xiaoyang [1 ]
机构
[1] Sichuan Univ, West China Hosp, Gen Practice Ward Int Med Ctr Ward, Gen Practice Med Ctr, 37 Guoxue Rd, Chengdu 610041, Peoples R China
[2] Sichuan Univ, West China Hosp, Dept Emergency Med, Chengdu, Sichuan, Peoples R China
[3] Sichuan Univ, Sch Comp Sci, Chengdu, Sichuan, Peoples R China
[4] Sichuan Univ, West China Hosp, West China Sch Med, Dept Cardiol, Chengdu, Sichuan, Peoples R China
关键词
Metabolic dysfunction-associated fatty liver disease; Disease trajectory; Mortality; Nonalcoholic fatty liver disease; EXTRAHEPATIC MANIFESTATIONS; CONFERS SUSCEPTIBILITY; ALCOHOL-CONSUMPTION; RISK; FIBROSIS; VARIANT; NAFLD;
D O I
10.1186/s12916-023-03080-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundMetabolic dysfunction-associated fatty liver disease (MAFLD) is a newly defined condition encompassing hepatic steatosis and metabolic dysfunction. However, the relationship between MAFLD and multi-system diseases remains unclear, and the time-dependent sequence of these diseases requires further clarification.MethodsAfter propensity score matching, 163,303 MAFLD subjects and 163,303 matched subjects were included in the community-based UK Biobank study. The International Classification of Diseases, Tenth Revision (ICD-10), was used to reclassify medical conditions into 490 and 16 specific causes of death. We conducted a disease trajectory analysis to map the key pathways linking MAFLD to various health conditions, providing an overview of their interconnections.ResultsParticipants aged 59 (51-64) years, predominantly males (62.5%), were included in the study. During the 12.9-year follow-up period, MAFLD participants were found to have a higher risk of 113 medical conditions and eight causes of death, determined through phenome-wide association analysis using Cox regression models. Temporal disease trajectories of MAFLD were established using disease pairing, revealing intermediary diseases such as asthma, diabetes, hypertension, hypothyroid conditions, tobacco abuse, diverticulosis, chronic ischemic heart disease, obesity, benign tumors, and inflammatory arthritis. These trajectories primarily resulted in acute myocardial infarction, disorders of fluid, electrolyte, and acid-base balance, infectious gastroenteritis and colitis, and functional intestinal disorders. Regarding death trajectories of MAFLD, malignant neoplasms, cardiovascular diseases, and respiratory system deaths were the main causes, and organ failure, infective disease, and internal environment disorder were the primary end-stage conditions. Disease trajectory analysis based on the level of genetic susceptibility to MAFLD yielded consistent results.ConclusionsIndividuals with MAFLD have a risk of a number of different medical conditions and causes of death. Notably, these diseases and potential causes of death constitute many pathways that may be promising targets for preventing general health decline in patients with MAFLD.
引用
收藏
页数:13
相关论文
共 53 条
  • [1] Metabolic dysfunction-associated fatty liver disease: a year in review
    Alharthi, Jawaher
    Gastaldelli, Amalia
    Cua, Ian Homer
    Ghazinian, Hasmik
    Eslam, Mohammed
    [J]. CURRENT OPINION IN GASTROENTEROLOGY, 2022, 38 (03) : 251 - 260
  • [2] The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD
    Angulo, Paul
    Hui, Jason M.
    Marchesini, Giulio
    Bugianesi, Ellisabetta
    George, Jacob
    Farrell, Geoffrey C.
    Enders, Felicity
    Saksena, Sushma
    Burt, Alastair D.
    Bida, John P.
    Lindor, Keith
    Sanderson, Schuyler O.
    Lenzi, Marco
    Adams, Leon A.
    Kench, James
    Therneau, Terry M.
    Day, Christopher P.
    [J]. HEPATOLOGY, 2007, 45 (04) : 846 - 854
  • [3] Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis
    Anstee, Quentin M.
    Targher, Giovanni
    Day, Christopher P.
    [J]. NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2013, 10 (06) : 330 - 344
  • [4] Extra-hepatic manifestations and complications of nonalcoholic fatty liver disease
    Ballestri, Stefano
    Mantovani, Alessandro
    Nascimbeni, Fabio
    Lugari, Simonetta
    Lonardo, Amedeo
    [J]. FUTURE MEDICINAL CHEMISTRY, 2019, 11 (16) : 2171 - 2192
  • [5] The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population
    Bedogni, Giorgio
    Bellentani, Stefano
    Miglioli, Lucia
    Masutti, Flora
    Passalacqua, Marilena
    Castiglione, Anna
    Tiribelli, Claudio
    [J]. BMC GASTROENTEROLOGY, 2006, 6 (1)
  • [6] Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma
    Behary, Jason
    Amorim, Nadia
    Jiang, Xiao-Tao
    Raposo, Anita
    Gong, Lan
    McGovern, Emily
    Ibrahim, Ragy
    Chu, Francis
    Stephens, Carlie
    Jebeili, Hazem
    Fragomeli, Vincenzo
    Koay, Yen Chin
    Jackson, Miriam
    O'Sullivan, John
    Weltman, Martin
    McCaughan, Geoffrey
    El-Omar, Emad
    Zekry, Amany
    [J]. NATURE COMMUNICATIONS, 2021, 12 (01)
  • [7] Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores
    Bianco, Cristiana
    Jamialahmadi, Oveis
    Pelusi, Serena
    Baselli, Guido
    Dongiovanni, Paola
    Zanoni, Irene
    Santoro, Luigi
    Maier, Silvia
    Liguori, Antonio
    Meroni, Marica
    Borroni, Vittorio
    D'Ambrosio, Roberta
    Spagnuolo, Rocco
    Alisi, Anna
    Federico, Alessandro
    Bugianesi, Elisabetta
    Petta, Salvatore
    Miele, Luca
    Vespasiani-Gentilucci, Umberto
    Anstee, Quentin M.
    Stickel, Felix
    Hampe, Jochen
    Fischer, Janett
    Berg, Thomas
    Fracanzani, Anna Ludovica
    Soardo, Giorgio
    Reeves, Helen
    Prati, Daniele
    Romeo, Stefano
    Valenti, Luca
    [J]. JOURNAL OF HEPATOLOGY, 2021, 74 (04) : 775 - 782
  • [8] Systematic review of discharge coding accuracy
    Burns, E. M.
    Rigby, E.
    Mamidanna, R.
    Bottle, A.
    Aylin, P.
    Ziprin, P.
    Faiz, O. D.
    [J]. JOURNAL OF PUBLIC HEALTH, 2012, 34 (01) : 138 - 148
  • [9] The UK Biobank resource with deep phenotyping and genomic data
    Bycroft, Clare
    Freeman, Colin
    Petkova, Desislava
    Band, Gavin
    Elliott, Lloyd T.
    Sharp, Kevin
    Motyer, Allan
    Vukcevic, Damjan
    Delaneau, Olivier
    O'Connell, Jared
    Cortes, Adrian
    Welsh, Samantha
    Young, Alan
    Effingham, Mark
    McVean, Gil
    Leslie, Stephen
    Allen, Naomi
    Donnelly, Peter
    Marchini, Jonathan
    [J]. NATURE, 2018, 562 (7726) : 203 - +
  • [10] Alcohol consumption and risk of fatty liver disease: a meta-analysis
    Cao, Guoli
    Yi, Tingzhuang
    Liu, Qianqian
    Wang, Min
    Tang, Shaohui
    [J]. PEERJ, 2016, 4